Investornewsbreaks Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Preliminary 2024 Financial Results
Tonix Pharmaceuticals (NASDAQ: TNXP) released selected preliminary financial results for 2024, reporting approximately $98.8 million in cash and cas ...
STAT4d
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...
Tonix stock gains on business update, preliminary earnings report
Tonix Pharmaceuticals (TNXP) stock jumped 11% Friday after the company issued a business update along with a preliminary 2024 ...
Tonix Pharmaceuticals reports positive topline trial outcomes of TNX-1500
Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...
What's Going On With Tonix Pharmaceuticals Shares Friday?
Tonix shares are moving higher on Friday after the company provided preliminary 2024 fiscal-year financial results.
Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash
Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities ...
Tonix reports preliminary Q4 net revenue $10.1M vs $7.8M last year
The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024. Maximize Your Portfolio with Data Driven ...
Tonix reports positive results in TNX-1500 phase 1 trial
CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a clinical-stage biotech company with a market capitalization of $28 million, announced today positive outcomes from its Phase 1 ...
MM&M6d
The Escalator: Astellas Pharma, Moderna, Minds + Assembly and more
Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...